"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Totect Patient Information including How Should I Take
In this Article
- What is dexrazoxane (Totect)?
- What are the possible side effects of dexrazoxane (Totect)?
- What is the most important information I should know about dexrazoxane (Totect)?
- What should I discuss with my health care provider before receiving dexrazoxane (Totect)?
- How is dexrazoxane given (Totect)?
- What happens if I miss a dose (Totect)?
- What happens if I overdose (Totect)?
- What should I avoid after receiving dexrazoxane (Totect)?
- What other drugs will affect dexrazoxane (Totect)?
- Where can I get more information?
What should I discuss with my health care provider before receiving dexrazoxane (Totect)?
You should not receive Zinecard if your chemotherapy does not include doxorubicin or a similar medication such as:
- daunorubicin (Cerubidine);
- epirubicin (Ellence);
- idarubicin (Idamycin); or
- mitoxantrone (Novantrone);
If possible before you receive dexrazoxane, tell your doctor if you have:
- liver disease;
- kidney disease; or
- if you are pregnant or breast-feeding.
Zinecard is rated as FDA pregnancy category C. It is not known whether Zinecard will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication.
Totect is rated as FDA pregnancy category D. Do not use Totect if you are pregnant. It could harm the unborn baby. If possible before you receive Zinecard, tell your doctor if you are pregnant.
It is not known whether dexrazoxane passes into breast milk or if it could harm a nursing baby. You should not breast-feed while you are using dexrazoxane.
In an emergency situation, it may not be possible before you are treated with Totect to tell your caregivers if you are pregnant or breast feeding. Make sure any doctor caring for your pregnancy or your baby knows you have received this medication.
How is dexrazoxane given (Totect)?
Dexrazoxane is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting.
Totect is usually started within 6 hours after extravasation, and continued once daily for 3 days.
Zinecard is usually started 30 minutes before you receive your doxorubicin injection.
Dexrazoxane can add to the bone marrow lowering effects of chemotherapy. This can weaken your immune system, making it easier for you to get sick from being around others who are ill.
To be sure this medication is not causing harmful effects, your blood cells and kidney function will need to be tested often. Do not miss any follow up visits to your doctor for blood or urine tests.
Additional Totect Information
- Totect Drug Interactions Center: dexrazoxane iv
- Totect Side Effects Center
- Totect Overview including Precautions
- Totect FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.